Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$9.88+0.09 (+0.92%)

Close on Nov 13, 2026Market cap $104.25MP/E –Yield –

Biodesix total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Biodesix's total debt was $47.15M at Sep 30, 2026. For fiscal 2025 it was $47.45M, up 30.3% from the year before. The highest annual figure on record is $47.45M in fiscal 2025.

Annual total debt

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$47.45M	+30.3%
FY2024	Dec 31, 2024	$36.41M	+3.4%
FY2023	Dec 31, 2023	$35.23M	+40.9%
FY2022	Dec 31, 2022	$25.00M	+150.2%
FY2021	Dec 31, 2021	$9.99M	-37.3%
FY2020	Dec 31, 2020	$15.93M	-33.1%
FY2019	Dec 31, 2019	$23.81M	–

Quarterly total debt

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$47.15M	+0.1%
Q2 FY2026	Jun 30, 2026	$46.82M	+0.1%
Q1 FY2026	Mar 31, 2026	$46.49M	+26.7%
Q4 FY2025	Dec 31, 2025	$47.45M	+30.3%
Q3 FY2025	Sep 30, 2025	$47.11M	+30.5%
Q2 FY2025	Jun 30, 2025	$46.78M	+30.7%
Q1 FY2025	Mar 31, 2025	$36.69M	+3.3%
Q4 FY2024	Dec 31, 2024	$36.41M	+3.4%
Q3 FY2024	Sep 30, 2024	$36.11M	+44.7%
Q2 FY2024	Jun 30, 2024	$35.81M	+45.2%
Q1 FY2024	Mar 31, 2024	$35.51M	+41.6%
Q4 FY2023	Dec 31, 2023	$35.23M	+40.9%
Q3 FY2023	Sep 30, 2023	$24.95M	+411.3%
Q2 FY2023	Jun 30, 2023	$24.66M	+186.9%
Q1 FY2023	Mar 31, 2023	$25.08M	+149.5%
Q4 FY2022	Dec 31, 2022	$25.00M	+150.2%
Q3 FY2022	Sep 30, 2022	$4.88M	-83.7%
Q2 FY2022	Jun 30, 2022	$8.60M	-71.3%
Q1 FY2022	Mar 31, 2022	$10.06M	-66.8%
Q4 FY2021	Dec 31, 2021	$9.99M	-37.3%
Q3 FY2021	Sep 30, 2021	$29.98M	+73.9%
Q2 FY2021	Jun 30, 2021	$29.96M	+25.8%
Q1 FY2021	Mar 31, 2021	$30.33M	–
Q4 FY2020	Dec 31, 2020	$15.93M	–
Q3 FY2020	Sep 30, 2020	$17.24M	–
Q4 FY2019	Dec 31, 2019	$23.81M	–